Stelara 130 mg/26 ml Injection 1's
₹97871.8*
MRP ₹111218
12% off
₹94535*
MRP ₹111218
15% CB
₹16683 cashback(15%)
Free Delivery
With Circle membership
(Inclusive of all Taxes)
This offer price is valid on orders above ₹800. Apply coupon PHARMA10/PHARMA18 (excluding restricted items)
Provide Delivery Location
Stelara 130 mg/26 ml Injection belongs to a class of monoclonal antibody drugs. It treats various inflammatory conditions, including Crohn's disease and active ulcerative colitis, in adults 18 years and older. It can treat moderate to severe psoriasis and psoriatic arthritis in adults and children six years and older. Crohn's disease is a chronic inflammatory disorder that affects the digestive tract. It is a kind of inflammatory bowel disease (IBD). Psoriasis is a skin disease that causes an itchy, scaly rash on the knees, elbows, trunk, and scalp. Crohn's disease is a chronic inflammatory disorder that affects the digestive tract. It's a form of inflammatory bowel illness.
Stelara 130 mg/26 ml Injection contains Ustekinumab, a monoclonal antibody that targets and neutralises specific proteins (interleukin-12 and interleukin-23) in the body that contribute to inflammation and immune responses.
Stelara 130 mg/26 ml Injection will be administered by a healthcare professional; do not self-administer. Sometimes, you may experience nasal congestion, runny nose, sore throat, fever, headache, tiredness, itching, nausea and vomiting, diarrhoea, stomach pain, joint pain and redness at the injection site. Most of these side effects of Stelara 130 mg/26 ml Injection do not require medical attention and gradually resolve over time. However, if the side effects persist or worsen, please consult your doctor.
Before taking the Stelara 130 mg/26 ml Injection, let your doctor know about all your medical conditions, sensitivities, and medications you are using. Also, inform your doctor if you are pregnant or breastfeeding. Stelara 130 mg/26 ml Injection may have an impact on your immune system. Stelara 130 mg/26 ml Injection can raise your risk of significant adverse effects. Stelara 130 mg/26 ml Injection may impair your ability to fight infections and put you at risk. Some patients get significant infections while taking Stelara 130 mg/26 ml Injection, such as tuberculosis (TB) and infections caused by bacteria, fungi, or viruses, which may necessitate hospitalization. It is strongly advised that you be tested for tuberculosis before beginning Stelara 130 mg/26 ml Injection treatment and that you be regularly monitored for signs and symptoms of tuberculosis while on Stelara 130 mg/26 ml Injection. If your doctor believes you are at risk for tuberculosis, you may be treated for it before and throughout your Stelara 130 mg/26 ml Injection treatment.
Stelara 130 mg/26 ml Injection contains Ustekinumab, a monoclonal antibody that targets and neutralises specific proteins (interleukin-12 and interleukin-23) in the body that contribute to inflammation and immune responses. Thus, it helps to treat Crohn’s disease and active ulcerative colitis in adults 18 years and older. It can treat moderate to severe psoriasis and psoriatic arthritis in adults and children six years and older.
Stelara 130 mg/26 ml Injection may suppress your immune system and raise your chance of some cancers and infections, so notify your doctor if you have any infections (bacterial/fungal/protozoal/viral), malignancies or cancers. Also, tell your doctor if you have tuberculosis or PRES (Posterior Reversible Encephalopathy Syndrome) or have ever had an adverse response to Ustekinumab or any of the components in this medicine. Stelara 130 mg/26 ml Injection may cause significant allergic responses in some cases. If you experience any of the following symptoms of a major allergic reaction: feeling faint, swelling of your face, eyelids, tongue, or throat, chest tightness, or skin rash, get medical attention immediately.
Drug-Drug Interactions: Stelara 130 mg/26 ml Injection may interact with monoclonal antibody medications (e.g. adalimumab), vaccinations (e.g. BCG vaccine, dengue vaccine), antirheumatic drug (e.g. leflunomide), and medicines used to treat multiple sclerosis-MS (e.g. natalizumab)
Drug-Food Interactions: Avoid consuming alcohol while on treatment with this medicine.
Drug-Disease Interactions: Caution is advised if used Stelara 130 mg/26 ml Injection in patients with Immunodeficiency, Skin cancers, active infections (Bacterial/Fungal/Protozoal/Viral), Tuberculosis (TB) and PRES (Posterior Reversible Encephalopathy Syndrome).
Ulcerative colitis: Ulcerative colitis is a type of chronic inflammatory bowel disease that causes inflammation of the lining of the large intestine (colon) and produces ulcers on the lining of the colon, which may cause bleeding and discharge of pus and mucus. The common symptoms include bloody stools, stomach pain, rectal pain, diarrhoea, and fever or weight loss. Additionally, it may cause other problems such as joint pain or swelling, mouth sores, skin problems, decreased appetite or nausea. The factors involved in causing ulcerative colitis include immune disorders and environmental factors like viruses, bacteria or antigens, which may trigger the immune system and genes inherited from the parent.
Crohn's disease: Crohn's disease is a chronic inflammatory disorder that affects the digestive tract. It is a kind of inflammatory bowel disease (IBD). The most common symptoms are diarrhoea, stomach aches and cramps, blood in your poo, exhaustion (fatigue), and weight loss.
Psoriasis: Psoriasis is a chronic autoimmune skin condition in which the skin multiplies ten times faster than usual. This causes a rapid accumulation of skin cells, resulting in scaling on the skin's surface. Inflamed, red, elevated areas of skin, soreness surrounding the patches, itching, burning feeling, swollen joints, and dry skin are all symptoms.
Psoriatic arthritis: Psoriatic arthritis is an arthritis that is associated with psoriasis, a persistent skin and nail disease.
Alcohol
Caution
Avoid consuming alcohol while on treatment with this medicine.
Pregnancy
Caution
The safety of Stelara 130 mg/26 ml Injection in pregnant women is unknown. Therefore, please consult your doctor; your doctor will weigh the benefits and potential risks before prescribing this medicine. Women of childbearing potential should take effective contraception throughout and for at least 15 weeks after therapy.
Breast Feeding
Caution
It is unknown whether Stelara 130 mg/26 ml Injection is excreted in human milk. It should not be used while breastfeeding unless the possible benefits outweigh the risks to the infant. Do not breastfeed unless your doctor recommends it if you are a nursing mother.
Driving
Caution
Drive only if you are alert, as the Stelara 130 mg/26 ml Injection may cause tiredness in some people.
Liver
Caution
Limited information was available about using Stelara 130 mg/26 ml Injection in patients with liver disease. Inform your doctor before receiving the Stelara 130 mg/26 ml Injection if you have a history of liver diseases/conditions. Your doctor will prescribe only if the benefits outweigh the risks.
Kidney
Caution
Limited information was available about using Stelara 130 mg/26 ml Injection in patients with kidney disease. Inform your doctor before receiving the Stelara 130 mg/26 ml Injection if you have a history of kidney diseases/conditions. Your doctor will prescribe only if the benefits outweigh the risks.
Children
Safe if prescribed
Stelara 130 mg/26 ml Injection can be used to treat severe psoriasis and psoriatic arthritis in children above six years of age.
Country of origin
Manufacturer/Marketer address
We provide you with authentic, trustworthy and relevant information